Cronos (CRON) 10-Q 8 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St. Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		381,089,357
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 409,428	$ 764,644
Short-term investments	431,510	113,077
Accounts receivable, net	12,540	23,113
Interest receivable	9,452	2,469
Other receivables	4,839	3,298
Current portion of loans receivable, net	5,035	8,890
Inventory, net	45,190	37,559
Prepaids and other current assets	6,780	7,106
Total current assets	924,774	960,156
Equity method investments, net	17,646	18,755
Other investments	67,925	70,993
Non-current portion of loans receivable, net	71,080	72,345
Property, plant and equipment, net	57,695	60,557
Right-of-use assets	1,571	2,273
Goodwill	1,057	1,033
Intangible assets, net	25,462	26,704
Deferred tax asset	1,137	193
Total assets	1,168,347	1,213,009
Current liabilities
Accounts payable	9,340	11,163
Income taxes payable	438	32,956
Accrued liabilities	16,573	22,268
Current portion of lease obligation	1,174	1,330
Derivative liabilities	37	15
Current portion due to non-controlling interests	364	384
Total current liabilities	27,926	68,116
Non-current portion due to non-controlling interests	1,023	1,383
Non-current portion of lease obligation	2,050	2,546
Deferred tax liability	675	0
Total liabilities	31,674	72,045
Shareholders’ equity
Share capital (authorized for issue as of June 30, 2023 and December 31, 2022: unlimited; shares outstanding as of June 30, 2023 and December 31, 2022: 381,089,357 and 380,575,403, respectively)	613,152	611,318
Additional paid-in capital	45,317	42,682
Retained earnings	463,153	490,682
Accumulated other comprehensive income (loss)	18,067	(797)
Total equity attributable to shareholders of Cronos Group	1,139,689	1,143,885
Non-controlling interests	(3,016)	(2,921)
Total shareholders’ equity	1,136,673	1,140,964
Total liabilities and shareholders’ equity	$ 1,168,347	$ 1,213,009

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	381,089,357	380,575,403
Common stock, shares outstanding (in shares)	381,089,357	380,575,403

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net revenue, before excise taxes	$ 25,798	$ 27,095	$ 52,352	$ 54,173
Excise taxes	(6,777)	(5,493)	(13,836)	(9,866)
Net revenue	19,021	21,602	38,516	44,307
Cost of sales	15,922	17,280	32,490	33,275
Gross profit	3,099	4,322	6,026	11,032
Operating expenses
Sales and marketing	5,297	4,185	11,038	7,195
Research and development	1,107	4,194	3,146	8,115
General and administrative	13,451	16,286	25,307	37,417
Restructuring costs	0	978	0	3,009
Share-based compensation	2,331	2,583	4,866	6,199
Depreciation and amortization	1,533	1,398	3,058	2,666
Impairment loss on long-lived assets	0	0	0	3,493
Total operating expenses	23,719	29,624	47,415	68,094
Operating loss	(20,620)	(25,302)	(41,389)	(57,062)
Other income
Interest income, net	12,471	3,775	23,646	5,820
Gain (loss) on revaluation of derivative liabilities	43	3,410	(22)	13,829
Share of income (loss) from equity method investments	270	5,197	(226)	5,197
Gain (loss) on revaluation of financial instruments	5,193	(2,112)	(2,565)	2,156
Impairment loss on other investments	0	0	0	(11,238)
Foreign currency transaction loss	(3,174)	(2,852)	(4,817)	(4,724)
Other, net	(26)	49	59	184
Total other income	14,777	7,467	16,075	11,224
Loss before income taxes	(5,843)	(17,835)	(25,314)	(45,838)
Income tax expense (benefit)	(180)	(308)	(1,616)	54
Loss from continuing operations	(5,663)	(17,527)	(23,698)	(45,892)
Loss from discontinued operations	(2,834)	(2,811)	(4,056)	(7,099)
Net loss	(8,497)	(20,338)	(27,754)	(52,991)
Net loss attributable to non-controlling interest	(137)	(117)	(225)	(132)
Net loss attributable to Cronos Group	(8,360)	(20,221)	(27,529)	(52,859)
Comprehensive income (loss)
Net loss	(8,497)	(20,338)	(27,754)	(52,991)
Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	16,580	(24,161)	18,994	(8,184)
Comprehensive income (loss)	8,083	(44,499)	(8,760)	(61,175)
Comprehensive income (loss) attributable to non-controlling interests	(87)	122	(95)	(139)
Comprehensive income (loss) attributable to Cronos Group	$ 8,170	$ (44,621)	$ (8,665)	$ (61,036)
Net loss per share
Basic - continuing operations (in dollars per share)	$ (0.01)	$ (0.05)	$ (0.06)	$ (0.12)
Diluted - continuing operations (in dollars per share)	(0.01)	(0.05)	(0.06)	(0.12)
Basic - discontinued operations (in dollars per share)	(0.01)	0	(0.01)	(0.02)
Diluted - discontinued operations (in dollars per share)	(0.01)	0	(0.01)	(0.02)
Basic (in dollars per share)	(0.02)	(0.05)	(0.07)	(0.14)
Diluted (in dollars per share)	$ (0.02)	$ (0.05)	$ (0.07)	$ (0.14)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2021		374,952,693
Beginning balance at Dec. 31, 2021	$ 1,334,276	$ 595,497	$ 32,465	$ 659,416	$ 49,865	$ (2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		347,287
Activities relating to share-based compensation	3,771	$ 871	2,900
Net loss	(32,653)			(32,638)		(15)
Foreign exchange gain (loss) on translation	15,977				16,223	(246)
Ending balance (in shares) at Mar. 31, 2022		375,299,980
Ending balance at Mar. 31, 2022	1,321,371	$ 596,368	35,365	626,778	66,088	(3,228)
Beginning balance (in shares) at Dec. 31, 2021		374,952,693
Beginning balance at Dec. 31, 2021	1,334,276	$ 595,497	32,465	659,416	49,865	(2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(52,991)
Foreign exchange gain (loss) on translation	(8,184)
Ending balance (in shares) at Jun. 30, 2022		377,896,371
Ending balance at Jun. 30, 2022	1,284,963	$ 604,626	35,198	606,557	41,688	(3,106)
Beginning balance (in shares) at Mar. 31, 2022		375,299,980
Beginning balance at Mar. 31, 2022	1,321,371	$ 596,368	35,365	626,778	66,088	(3,228)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		395,156
Activities relating to share-based compensation	$ 2,084	$ 2,251	(167)	0
Share issuance pursuant to research and development milestones (in shares)	2,201,235
Share issuance pursuant to research and development milestones	$ 6,007	$ 6,007
Net loss	(20,338)			(20,221)		(117)
Foreign exchange gain (loss) on translation	(24,161)				(24,400)	239
Ending balance (in shares) at Jun. 30, 2022		377,896,371
Ending balance at Jun. 30, 2022	$ 1,284,963	$ 604,626	35,198	606,557	41,688	(3,106)
Beginning balance (in shares) at Dec. 31, 2022	380,575,403	380,575,403
Beginning balance at Dec. 31, 2022	$ 1,140,964	$ 611,318	42,682	490,682	(797)	(2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		240,518
Activities relating to share-based compensation	2,279	$ 917	1,362
Net loss	(19,257)			(19,169)		(88)
Foreign exchange gain (loss) on translation	2,414				2,334	80
Ending balance (in shares) at Mar. 31, 2023		380,815,921
Ending balance at Mar. 31, 2023	$ 1,126,400	$ 612,235	44,044	471,513	1,537	(2,929)
Beginning balance (in shares) at Dec. 31, 2022	380,575,403	380,575,403
Beginning balance at Dec. 31, 2022	$ 1,140,964	$ 611,318	42,682	490,682	(797)	(2,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,754)
Foreign exchange gain (loss) on translation	$ 18,994
Ending balance (in shares) at Jun. 30, 2023	381,089,357	381,089,357
Ending balance at Jun. 30, 2023	$ 1,136,673	$ 613,152	45,317	463,153	18,067	(3,016)
Beginning balance (in shares) at Mar. 31, 2023		380,815,921
Beginning balance at Mar. 31, 2023	1,126,400	$ 612,235	44,044	471,513	1,537	(2,929)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		273,436
Activities relating to share-based compensation	2,190	$ 917	1,273
Net loss	(8,497)			(8,360)		(137)
Foreign exchange gain (loss) on translation	$ 16,580				16,530	50
Ending balance (in shares) at Jun. 30, 2023	381,089,357	381,089,357
Ending balance at Jun. 30, 2023	$ 1,136,673	$ 613,152	$ 45,317	$ 463,153	$ 18,067	$ (3,016)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net loss	$ (27,754)	$ (52,991)
Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation	4,887	6,302
Depreciation and amortization	4,785	7,051
Impairment loss on long-lived assets	205	3,493
Impairment loss on other investments	0	11,238
Loss (gain) from investments	2,955	(7,193)
Loss (gain) on revaluation of derivative liabilities	22	(13,829)
Changes in expected credit losses on long-term financial assets	(1,146)	(655)
Foreign currency transaction loss	4,817	4,724
Other non-cash operating activities, net	(4,012)	(1,956)
Changes in operating assets and liabilities:
Accounts receivable, net	10,623	1,981
Interest receivable	(6,807)	(383)
Other receivables	(200)	3,973
Prepaids and other current assets	480	(3,759)
Inventory	(7,259)	(8,145)
Accounts payable	(2,478)	481
Income taxes payable	(32,801)	0
Accrued liabilities	(5,784)	(1,523)
Cash flows used in operating activities	(59,467)	(51,191)
Investing activities
Purchase of short-term investments	(479,763)	(157,300)
Proceeds from short-term investments	169,418	117,975
Dividends received from equity method investment	1,299	0
Proceeds from repayment on loan receivables	11,388	1,573
Purchase of property, plant and equipment	(1,298)	(2,218)
Purchase of intangible assets	(8)	(421)
Other investing activities	0	70
Cash flows used in investing activities	(298,964)	(40,321)
Financing activities
Withholding taxes paid on share-based awards	(782)	(2,080)
Other financing activities, net	0	46
Cash flows used in financing activities	(782)	(2,034)
Effect of foreign currency translation on cash and cash equivalents	3,997	(3,884)
Net change in cash and cash equivalents	(355,216)	(97,430)
Cash and cash equivalents, beginning of period	764,644	886,973
Cash and cash equivalents, end of period	409,428	789,543
Supplemental cash flow information
Interest paid	0	0
Interest received	13,385	3,490
Income taxes paid	$ 32,995	$ 140

Background, Basis of Presentati

Background, Basis of Presentation, and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation, and Summary of Significant Accounting Policies	Background, Basis of Presentation, and Summary of Significant Accounting Policies (a) Background Cronos Group Inc. (“Cronos” or the “Company”) is incorporated in the province of British Columbia under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . (b) Basis of presentation These condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”). Certain prior period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (c) Discontinued Operations In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations. (d) Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Historically, the Company has reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These reclassifications had no effect on our consolidated financial statements in any period presented. (e) Revenue recognition The following tables present the Company's revenue by major product category for continuing operations: Three months ended June 30, 2023 2022 Cannabis flower $ 14,014 $ 15,739 Cannabis extracts 4,926 5,582 Other 81 281 Net revenue $ 19,021 $ 21,602 Six months ended June 30, 2023 2022 Cannabis flower $ 27,142 $ 34,364 Cannabis extracts 11,227 9,570 Other 147 373 Net revenue $ 38,516 $ 44,307 Net revenue attributed to a geographic region based on the location of the customer were as follows for continuing operations: Three months ended June 30, 2023 2022 Canada $ 13,595 $ 14,389 Israel 5,426 7,213 Net revenue $ 19,021 $ 21,602 Six months ended June 30, 2023 2022 Canada $ 28,029 $ 27,965 Israel 10,487 16,342 Net revenue $ 38,516 $ 44,307 (f) Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $943,884 and $987,836 as of June 30, 2023 and December 31, 2022, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, 2023 and December 31, 2022, the Company had $69 and $219, respectively, in expected credit losses that have been recognized on receivables from contracts with customers. As of June 30, 2023, the Company assessed that there is a concentration of credit risk, as 41% of the Company’s accounts receivable were due from two customers with an established credit history with the Company. As of December 31, 2022, 55% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended June 30, 2023, the Company earned a total net revenue before excise taxes of $16,839 from three major customers, together accounting for 67% of the Company’s total net revenues before excise taxes. During the three months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $12,767 from three major customers, together accounting for 59% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2023, the Company earned a total net revenue before excise taxes of $34,732 from three major customers, together accounting for 67% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2022, the Company earned a total net revenue before excise taxes of $24,690 from three major customers, together accounting for 56% of the Company’s total net revenues before excise taxes. (g) Adoption of new accounting pronouncements On January 1, 2023, the Company adopted ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. The adoption of ASU No. 2022-02 did not have a material impact on the Company’s condensed consolidated interim financial statements. (h) New accounting pronouncements not yet adopted In June 2022, the Financial Accounting Standards Board (“FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and we expect to adopt ASU 2022-03 prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations In the second quarter of 2023, the Company exited its then-existing U.S. hemp-derived cannabinoid product operations. Accordingly, the net loss of the U.S. operations for the three and six months ended June 30, 2023 and 2022 are reported separately as loss from discontinued operations on the condensed consolidated statements of net loss and comprehensive income (loss). The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Net revenue $ 380 $ 1,459 $ 1,029 $ 3,787 Cost of sales 848 1,661 2,044 3,773 Inventory write-down 839 — 839 — Gross profit (1,307) (202) (1,854) 14 Operating expenses Sales and marketing 387 1,397 518 3,399 Research and development 18 108 20 226 General and administrative 213 719 736 1,956 Restructuring costs 534 292 534 1,345 Share-based compensation 5 33 21 103 Depreciation and amortization 5 13 13 38 Impairment loss on long-lived assets (ii) 205 — 205 — Total operating expenses 1,367 2,562 2,047 7,067 Interest income 3 — 8 1 Other, net (i) (163) (47) (163) (47) Total other loss (160) (47) (155) (46) Loss before income taxes (2,834) (2,811) (4,056) (7,099) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (2,834) $ (2,811) $ (4,056) $ (7,099) (i) For the three and six months ended June 30, 2023 and June 30, 2022, Other, net related to loss on disposal of assets that were part of the U.S. operations. (ii) During the three and six months ended June 30, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California. The following tables present the Company's discontinued operations revenue by major product category: Three months ended June 30, 2023 2023 2022 Cannabis extracts $ 380 $ 1,459 Net revenue $ 380 $ 1,459 Six months ended June 30, 2023 2022 Cannabis extracts $ 1,029 $ 3,787 Net revenue $ 1,029 $ 3,787 The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023 and 2022: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 102 $ 292 $ (328) $ 66 Total $ 102 $ 292 $ (328) $ 66 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,345 $ (1,279) $ 66 Total $ — $ 1,345 $ (1,279) $ 66 The following table presents a reconciliation of assets and liabilities of the discontinued operations presented in the condensed consolidated balance sheets: As of June 30, 2023 As of December 31, 2022 Assets Current assets Cash and cash equivalents $ 1,918 $ 2,300 Accounts receivable, net 7 253 Other receivables — 775 Prepaids and other current assets 53 464 Inventory, net — 934 Current assets of discontinued operations 1,978 4,726 Non-current assets Property, plant and equipment, net — 254 Right-of-use assets — 430 Intangible assets, net — 1,594 Non-current assets of discontinued operations — 2,278 Liabilities Current liabilities Accounts payable 131 166 Accrued liabilities 621 807 Current portion of lease obligation 216 415 Current liabilities of discontinued operations $ 968 $ 1,388 For the six months ended June 30, 2023, purchases of property plant and equipment related to discontinued operations were $67. For the six months ended June 30, 2022 purchases of property plant and equipment related to discontinued operations were $133.

Inventory, net

Inventory, net	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory, net	Inventory, net Inventory, net is comprised of the following items: As of June 30, 2023 As of December 31, 2022 Raw materials $ 7,419 $ 7,421 Work-in-progress 15,926 15,646 Finished goods 20,730 13,503 Supplies and consumables 1,115 989 Total $ 45,190 $ 37,559

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments (a) Equity method investments, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2023 As of December 31, 2022 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 17,646 $ 18,755 $ 17,646 $ 18,755 On June 30, 2023, the Company received a dividend of C$1,750 ($1,322) from Cronos GrowCo, which reduced the Company’s carrying amount in the investment. The following is a summary of the Company’s share of net gain (loss) from equity method investments: For the three months ended June 30, For the six months ended June 30, 2023 2022 2023 2022 Cronos GrowCo $ 270 $ 5,197 $ (226) $ 5,197 $ 270 $ 5,197 $ (226) $ 5,197 (b) Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann, Inc. In 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, which represented an ownership interest of approximately 10.5% as of the purchase date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The PharmaCann Option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the PharmaCann Option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of June 30, 2023, the Company’s proforma ownership percentage in PharmaCann on a fully-diluted basis was approximately 6.3%. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option. Vitura Health Limited (formerly known as Cronos Australia) The Company owns approximately 10% of the outstanding common shares of Vitura Health Limited (“Vitura”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive income (loss). The PharmaCann Option is measured at fair value on a non-recurring basis and is a level 3 asset. See Note 11 “ Fair Value Measurements ” for more information on the fair value hierarchy. The following table summarizes the Company’s other investments activity: As of April 1, 2023 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 13,833 5,194 — (102) 18,925 $ 62,833 $ 5,194 $ — $ (102) $ 67,925 As of January 1, 2023 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 21,993 (2,729) — (339) 18,925 $ 70,993 $ (2,729) $ — $ (339) $ 67,925 As of April 1, 2022 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 99,154 $ — $ — $ — $ 99,154 Vitura 12,607 (2,200) — (892) 9,515 $ 111,761 $ (2,200) $ — $ (892) $ 108,669 As of January 1, 2022 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Vitura 8,000 1,996 — (481) 9,515 $ 118,392 $ 1,996 $ (11,238) $ (481) $ 108,669 During the six months ended June 30, 2022, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the market and income approaches. Under the income approach, significant inputs used in the discounted cash flow method were the discount rate, growth rates, cash flow projections, and the timing of federal legalization of cannabis in the U.S. Under the market valuation approach, the key assumptions that require judgment under the Guideline Public Companies method are cash flow projections, selected multiples and the discount for lack of marketability. As a result of this analysis, the Company recorded a non-cash impairment charge of $11,238 during the six months ended June 30, 2022, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value in the condensed consolidated statements of net loss and comprehensive income (loss).

Loans Receivable, net

Loans Receivable, net	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Loans Receivable, net	Loans Receivable, net Loans receivable, net consists of the following: As of June 30, 2023 As of December 31, 2022 GrowCo Credit Facility $ 5,035 $ 4,427 Add: Current portion of accrued interest — 4,463 Total current portion of loans receivable 5,035 8,890 GrowCo Credit Facility 55,757 56,898 Mucci Promissory Note 13,383 13,438 Cannasoul Collaboration Loan 1,736 1,837 Add: Long-term portion of accrued interest 204 172 Total long-term portion of loans receivable 71,080 72,345 Total loans receivable, net $ 76,115 $ 81,235 Cronos GrowCo Credit Facility On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Credit Facility”). In August 2021, the GrowCo Credit Facility was amended to increase the aggregate principal amount available to C$105,000. As of both June 30, 2023 and December 31, 2022, Cronos GrowCo had drawn C$104,000 ($78,538 and $76,730, respectively) from the GrowCo Credit Facility. The interest rate on the outstanding borrowings is the Canadian Prime Rate plus 1.25%, with interest payments due on December 2021, December 2022, and quarterly thereafter. Principal payments of C$1,000 commenced in March 2022 and are due quarterly thereafter. As of June 30, 2023, Cronos GrowCo had repaid C$8,167 ($6,167) and C$16,486 ($12,450) in principal and interest, respectively, under the terms of the GrowCo Credit Facility. Mucci Promissory Note On June 28, 2019, the Company entered into a promissory note receivable agreement (the “Mucci Promissory Note”) for C$16,350 (approximately $12,347) with the Cronos GrowCo joint venture partner (“Mucci”). The Mucci Promissory Note is secured by a general security agreement covering all the assets of Mucci. On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, change the interest payments from quarterly to annual, and defer Mucci’s initial cash interest payment from September 30, 2022 to July 1, 2023. Prior to July 1, 2022, interest accrued on the Mucci Promissory Note was capitalized as part of the principal balance. As of July 1, 2022, interest was accrued and to be paid in cash beginning on July 1, 2023. On June 30, 2023, Mucci made a payment of C$1,750 (approximately $1,322) under the Mucci Promissory Note, with C$1,187 ($897) related to accrued interest and C$563 ($425) related to outstanding principal. Cannasoul Collaboration Loan As of both June 30, 2023 and December 31, 2022, Cannasoul Lab Services Ltd. has received ILS 8,297 (approximately $2,239 and $2,359, respectively), from the Cannasoul Collaboration Loan. Expected credit loss allowances on the Company’s long-term financial assets for the three and six months ended June 30, 2023 and 2022 were comprised of the following items: As of April 1, 2023 Increase (decrease) (i) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 11,719 $ (379) $ 239 $ 11,579 Mucci Promissory Note 91 (7) 2 86 Cannasoul Collaboration Loan 514 4 (15) 503 $ 12,324 $ (382) $ 226 $ 12,168 As of April 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Credit Facility $ 14,354 $ (660) $ (401) $ 13,293 Mucci Promissory Note 93 1 (3) 91 Cannasoul Collaboration Loan 409 4 (36) 377 $ 14,856 $ (655) $ (440) $ 13,761 As of January 1, 2023 Increase (decrease) (i) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 12,455 $ (1,149) $ 273 $ 11,579 Mucci Promissory Note 89 (5) 2 86 Cannasoul Collaboration Loan 522 8 (27) 503 $ 13,066 $ (1,146) $ 248 $ 12,168 As of January 1, 2022 Increase (decrease) Foreign exchange effect As of June 30, 2022 GrowCo Credit Facility $ 14,089 $ (664) $ (132) $ 13,293 Mucci Promissory Note 90 2 (1) 91 Cannasoul Collaboration Loan 415 7 (45) 377 $ 14,594 $ (655) $ (178) $ 13,761 (i) During the three and six months ended June 30, 2023, $382 and $1,146, respectively, were recorded as decreases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of principal and interest payments made by Cronos GrowCo reducing our expected credit losses on loans receivable. During both the three and six months ended June 30, 2022, $655 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of adjustments to our expected credit losses.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Derivative Liabilities Pursuant to the investor rights agreement (the “Investor Rights Agreement”) between the Company and Altria Group Inc. (“Altria”), the Company granted Altria certain rights, among others, summarized in this note . The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement. a. The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Collaboration Agreement will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. b. In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”). The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the 10 full days preceding such exercise by Altria; provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities on the Company’s consolidated balance sheet. As of June 30, 2023, Altria beneficially held 156,573,537 of the Company’s common shares, an approximate 41% ownership interest in the Company (calculated on a non-diluted basis). Reconciliation of the Company’s derivative liabilities activity are as follows: As of April 1, 2023 Revaluation (gain) loss Foreign exchange effect As of June 30, 2023 Pre-emptive Rights $ 79 $ (43) $ 1 $ 37 Top-up Rights 1 — (1) — $ 80 $ (43) $ — $ 37 As of April 1, 2022 Revaluation gain Foreign exchange effect As of June 30, 2022 Altria Warrant $ 3,845 $ (3,245) $ (109) $ 491 Pre-emptive Rights 67 (49) (2) 16 Top-up Rights 187 (116) (4) 67 $ 4,099 $ (3,410) $ (115) $ 574 As of January 1, 2023 Revaluation (gain) loss Foreign exchange effect As of June 30, 2023 Pre-emptive Rights $ — $ 36 1 $ 37 Top-up Rights 15 (14) (1) — $ 15 $ 22 $ — $ 37 As of January 1, 2022 Revaluation gain Foreign exchange effect As of June 30, 2022 Altria Warrant $ 13,720 $ (13,256) $ 27 $ 491 Pre-emptive Rights 180 (164) — 16 Top-up Rights 475 (409) 1 67 $ 14,375 $ (13,829) $ 28 $ 574 Fluctuations in the expected life of the derivative instruments and the Company’s share price are primary drivers for the changes in the derivative valuations during each reporting period. As the period of time that the derivative liability is expected to be outstanding decreases and the share price decreases, the fair value typically decreases for each related derivative instrument. Weighted-average expected life and share price are two of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of June 30, 2023 Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $2.61 $2.61 Subscription price (per share in C$) $16.25 $16.25 Weighted-average risk-free interest rate (i) 4.72% 4.86% Weighted-average expected life (in years) (ii) 1.50 1.10 Expected annualized volatility (iii) 59% 59% Expected dividend yield —% —% As of December 31, 2022 Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $3.44 $3.44 Subscription price (per share in C$) $16.25 $16.25 Weighted-average risk-free interest rate (i) 4.14% 4.28% Weighted-average expected life (in years) (ii) 0.25 0.59 Expected annualized volatility (iii) 73% 73% Expected dividend yield —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2023 and December 31, 2022, the risk-free interest rate uses a range of approximately 4.46% to 4.89% and 3.81% to 4.37%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2023 and December 31, 2022, the expected life uses a range of approximately 1.00 years to 2.25 years and 0.25 years to 2.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Peace Naturals Campus”). On February 27, 2023, the Board approved revisions to the Realignment, which are expected to result in the Company maintaining select components of its operations at the Peace Naturals Campus, namely distribution warehousing, certain research and development activities and manufacturing of certain of the Company’s products, while seeking to sell and lease back all or some of the Peace Naturals Campus or to lease certain portions of the Peace Naturals Campus to third parties. The Realignment initiatives were intended to position the Company to drive profitable and sustainable growth over time. During the three and six months ended June 30, 2022, the Company recognized $978 and $3,009, respectively, of restructuring costs in connection with the Realignment, including the change in the nature of operations at the Peace Naturals Campus. Charges related thereto include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. During the three and six months ended June 30, 2023, the Company incurred no restructuring costs in its continuing operations. Restructuring costs incurred in the Company’s discontinued operations during the three and six months ended June 30, 2023 and 2022 is presented in Note 2 “ Discontinued Operations .” The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022: Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 1,152 $ 140 $ (470) $ 822 Other Restructuring Costs 144 838 (961) 21 Total $ 1,296 $ 978 $ (1,431) $ 843 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,590 $ (768) $ 822 Other Restructuring Costs — 1,419 (1,398) 21 Total $ — $ 3,009 $ (2,166) $ 843

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan. The following table summarizes the total share-based compensation expense associated with the Company’s stock options, RSUs and liability-classified awards for the three and six months ended June 30, 2023 and 2022: Three months ended June 30, For the six months ended June 30, 2023 2022 2023 2022 Stock options $ 372 $ 1,141 $ 1,106 $ 2,870 RSUs 1,959 1,442 3,760 3,329 Total share-based compensation $ 2,331 $ 2,583 $ 4,866 $ 6,199 (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three three The following is a summary of the changes in stock options for the six months ended June 30, 2023 and 2022: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2023 $ 10.57 5,350,600 0.73 Issuance of options 2.96 188,317 Cancellation, forfeiture and expiry of options 7.75 (3,435,716) Balance as of June 30, 2023 $ 14.50 2,103,201 2.34 Exercisable as of June 30, 2023 $ 18.72 1,426,612 1.00 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.11 (1,481,004) Cancellation, forfeiture and expiry of options 13.56 (89,251) Balance as of June 30, 2022 $ 8.61 7,369,075 1.53 Exercisable as of June 30, 2022 $ 8.28 4,686,991 1.04 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. For the six months ended June 30, 2023, the weighted-average fair value per option at grant date was C$2.07. The fair value of the options issued during the period was determined using the Black-Scholes option pricing model, using the following inputs: 2023 Share price at grant date (per share) $2.96 Exercise price (per option) $2.96 Risk-free interest rate 3.22% Expected life of options (in years) 7 Expected annualized volatility 72.68% Expected dividend yield — Weighted average Black-Scholes value at grant date (per option) $2.07 Forfeiture rate — The following table summarizes stock options outstanding: As of June 30, 2023 As of December 31, 2022 2020 Omnibus Plan 702,264 2,788,947 2018 Stock Option Plan 1,400,937 1,422,069 2015 Stock Option Plan — 1,139,584 Total stock options outstanding 2,103,201 5,350,600 (c) Restricted share units The following is a summary of the changes in RSUs for the six months ended June 30, 2023 and 2022: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2023 $ 4.63 5,725,470 Granted (i) 2.66 2,819,174 Vested and issued 5.04 (735,523) Cancellation and forfeitures 3.93 (254,382) Balance as of June 30, 2023 $ 3.87 7,554,739 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 4.32 4,513,992 Vested and issued 8.58 (722,721) Cancellation and forfeitures 8.32 (101,561) Balance as of June 30, 2022 $ 4.84 4,915,580 (i) RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three (ii) The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs for the six months ended June 30, 2023 and 2022: Financial liability Number of DSUs Balance as of January 1, 2023 $ 674 265,732 Gain on revaluation (150) — Balance as of June 30, 2023 $ 524 265,732 Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (161) — Balance as of June 30, 2022 $ 247 104,442

Loss per Share

Loss per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Loss per Share	Loss per Share Basic and diluted loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Basic and diluted loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (5,526) $ (17,410) $ (23,473) $ (45,760) Weighted-average number of common shares outstanding for computation for basic and diluted loss per share (i) 380,961,682 376,031,860 380,792,802 375,530,077 Basic loss from continuing operations per share $ (0.01) $ (0.05) $ (0.06) $ (0.12) Diluted loss per share from continuing operations $ (0.01) $ (0.05) $ (0.06) $ (0.12) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (2,834) $ (2,811) $ (4,056) $ (7,099) Weighted-average number of common shares outstanding for computation for basic and diluted loss per share (i) 380,961,682 376,031,860 380,792,802 375,530,077 Basic loss from discontinued operations per share $ (0.01) $ 0.00 $ (0.01) $ (0.02) Diluted loss from discontinued operations per share $ (0.01) $ 0.00 $ (0.01) $ (0.02) (i) In computing diluted loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended June 30, 2023 and 2022, total securities of 28,769,758 and 119,589,123, respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive. For the six months ended June 30, 2023 and 2022, total securities of 29,428,093 and 118,906,603, respectively, were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and now former Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal control were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board’s review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names (i) the Company, (ii) its Chief Executive Officer, (iii) now former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal control were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice, and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court’s dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court. (ii) Regulatory reviews relating to restatements The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019 as well as the previously disclosed restatement of the second quarter of 2021 interim financial statements (collectively, the “Restatements”). The Company has been responding to all such requests for information and cooperating with all regulatory authorities. SEC Settlement On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933 (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the Restatements. The Company has agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposes of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount. The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. Additionally, the Company agreed to certain undertakings, which include, among other things, retaining a qualified independent consultant (the “Consultant”) to engage in a review of, and make recommendations with respect to, certain of the Company’s internal accounting controls and internal control over financing reporting. The Consultant’s review has been completed. As a result of the Settlement Order, the Company (i) lost its status as a well-known seasoned issuer for a period of three years, (ii) is unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) is unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years. OSC Settlement On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the OSC, resolving the Restatements. Pursuant to the terms of the Settlement Agreement, which fully and finally disposed the investigation of the Company by the OSC, Cronos agreed to pay a total of C$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Securities Act (Ontario) to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. Additionally, the Company agreed to retain the Consultant to engage in a review of, and make recommendations with respect to, certain of the Company’s internal accounting controls and internal control over financing reporting, on substantially the same terms as were required by the SEC pursuant the Settlement Agreement. The Consultant’s review has been completed. (iii) Litigation relating to marketing, distribution and sale of products On April 17, 2023, a group of plaintiffs led by the Green Leaf (Ale Yarok) political party filed a Statement of Claim and Request for Approval of a Class Action on behalf of a purported class of Israeli cannabis consumers in the District Court of Tel Aviv, Israel, against 26 cannabis-related parties, including three Cronos Israel entities. The Statement of Claim alleges that the defendants violated certain laws relating to the marketing of medical cannabis products, including marketing to unlicensed cannabis consumers. The lawsuit seeks a total of ILS 420 million.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Risks and Uncertainties [Abstract]
Fair Value Measurements	Fair Value Measurements The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 409,428 $ — $ — $ 409,428 Short-term investments 431,510 — — 431,510 Other investments (i) 18,925 — — 18,925 Derivative liabilities — — 37 37 December 31, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 764,644 $ — $ — $ 764,644 Short-term investments 113,077 — — 113,077 Other investments (i) 21,993 — — 21,993 Derivative liabilities — — 15 15 (i) As of June 30, 2023 and December 31, 2022, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “Investments” for additional information. There were no transfers between fair value categories during the periods presented. The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: As of June 30, 2023 Level 1 Level 2 Level 3 Total Other investments (i) — — 49,000 49,000 As of December 31, 2022 Level 1 Level 2 Level 3 Total Other investments (i) — — 49,000 49,000 (i) On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell Holdings Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (“the LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of both June 30, 2023 and December 31, 2022, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.3%. See Note 4 “ Investments .” There were no transfers between fair value categories during the periods presented.

Impairment Loss on Long-lived A

Impairment Loss on Long-lived Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss on Long-lived Assets	Impairment Loss on Long-lived Assets (a) Right-of-use assets and property, plant, and equipment, net During the six months ended June 30, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters, encompassing approximately 29,000 square feet, in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease. In addition, the Company recognized an impairment charge of $1,507 during the six months ended June 30, 2022 related to leasehold improvements and other office equipment that it plans to include in any potential sublease agreement. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net loss and comprehensive income (loss).

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions (a) Cronos GrowCo The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 4 “ Investments ” for additional information. The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Cronos GrowCo - purchases $ 6,549 $ 5,597 $ 14,015 $ 8,815 As of June 30, 2023, and December 31, 2022, the Company had payables outstanding to Cronos GrowCo of $2,682 and $2,519, respectively. Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 5 “ Loans Receivable, net ” for additional information. (b) Vendor Agreement In November 2022, the Company entered into an agreement with an external vendor whereby the vendor would provide certain manufacturing services to the Company. The vendor then subcontracted out a portion of those services to another company whose chief executive officer is an immediate family member of an executive of the Company. The Company has no direct contractual relationship with the related party. During the three and six months ended June 30, 2023, the Company purchased $603 and $1,436, respectively, of products and services under this agreement and had outstanding accounts payable related to the agreement of $45 and $nil as of June 30, 2023 and December 31, 2022, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events (a) Planned Exit of the Fermentation Facility On August 4, 2023, the Board approved plans to wind-down operations at its Winnipeg, Manitoba facility (“Cronos Fermentation”) and list the Cronos Fermentation facility for sale. The Company expects to incur approximately $1,200 in restructuring costs associated with the exit of Cronos Fermentation facility. These charges include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2023, but do not include any impairment charges to property, plant or equipment. These anticipated charges are subject to a number of assumptions, including the ability to wind down Cronos Fermentation efficiently and effectively, the length of the sales process, the bids received in the sale process, market factors and others. As a result of these assumptions, actual results may differ materially. The Company cannot, at this time, quantify the impairment charges, if any, to long-lived assets associated with the wind-down. (b) Cost Reductions Also on August 4, 2023, the Board approved additional organization-wide cost reductions. Expected restructuring costs of approximately $2,000, with the majority expected to be incurred in the second half of 2023, include mostly one-time employee-related severance charges. These anticipated costs are subject to a number of assumptions, including the ability of the Company to effectively and efficiently further streamline operations, the number of employee reductions, the timing of employee reductions, the level of the Company’s operations, market factors and others. As a result of these assumptions, actual results may differ materially.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ (8,360)	$ (20,221)	$ (27,529)	$ (52,859)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Background, Basis of Presenta_2

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation These condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”). Certain prior period amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.
Discontinued Operations	Discontinued Operations In the second quarter of 2023, the Company exited its U.S. hemp-derived cannabinoid product operations. The exit of the U.S. operations represented a strategic shift that has a major effect on the Company’s operations and financial results, and as such, qualifies for reporting as discontinued operations in our condensed consolidated statements of net loss and comprehensive income (loss). Prior period amounts have been reclassified to reflect the discontinued operations classification of the U.S. operations.
Segment information	Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. Historically, the Company has reported results for two reportable segments, the U.S. and Rest of World. In the second quarter of 2023, as a result of the Company’s exit of its then-existing U.S. operations, the Company determined that it has one operating segment and therefore one reportable segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . All prior period segment disclosure information has been reclassified to conform to the current reporting structure in this Form 10-Q. These reclassifications had no effect on our consolidated financial statements in any period presented.
Concentration of risk	Concentration of riskCredit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments and loans receivable. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $943,884 and $987,836 as of June 30, 2023 and December 31, 2022, respectively.An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due.
Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements On January 1, 2023, the Company adopted ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. The adoption of ASU No. 2022-02 did not have a material impact on the Company’s condensed consolidated interim financial statements. (h) New accounting pronouncements not yet adopted In June 2022, the Financial Accounting Standards Board (“FASB”) issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU No. 2022-03”). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and we expect to adopt ASU 2022-03 prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

Background, Basis of Presenta_3

Background, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue by Major Product Category	The following tables present the Company's revenue by major product category for continuing operations: Three months ended June 30, 2023 2022 Cannabis flower $ 14,014 $ 15,739 Cannabis extracts 4,926 5,582 Other 81 281 Net revenue $ 19,021 $ 21,602 Six months ended June 30, 2023 2022 Cannabis flower $ 27,142 $ 34,364 Cannabis extracts 11,227 9,570 Other 147 373 Net revenue $ 38,516 $ 44,307
Schedule of Revenue from External Customers by Geographic Areas	Net revenue attributed to a geographic region based on the location of the customer were as follows for continuing operations: Three months ended June 30, 2023 2022 Canada $ 13,595 $ 14,389 Israel 5,426 7,213 Net revenue $ 19,021 $ 21,602 Six months ended June 30, 2023 2022 Canada $ 28,029 $ 27,965 Israel 10,487 16,342 Net revenue $ 38,516 $ 44,307

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Summary of Financial Information for Discontinued Operations	The following table presents the major components comprising loss from discontinued operations in the condensed consolidated statements of operations for the three and six months ended June 30, 2023 and 2022: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Net revenue $ 380 $ 1,459 $ 1,029 $ 3,787 Cost of sales 848 1,661 2,044 3,773 Inventory write-down 839 — 839 — Gross profit (1,307) (202) (1,854) 14 Operating expenses Sales and marketing 387 1,397 518 3,399 Research and development 18 108 20 226 General and administrative 213 719 736 1,956 Restructuring costs 534 292 534 1,345 Share-based compensation 5 33 21 103 Depreciation and amortization 5 13 13 38 Impairment loss on long-lived assets (ii) 205 — 205 — Total operating expenses 1,367 2,562 2,047 7,067 Interest income 3 — 8 1 Other, net (i) (163) (47) (163) (47) Total other loss (160) (47) (155) (46) Loss before income taxes (2,834) (2,811) (4,056) (7,099) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (2,834) $ (2,811) $ (4,056) $ (7,099) (i) For the three and six months ended June 30, 2023 and June 30, 2022, Other, net related to loss on disposal of assets that were part of the U.S. operations. (ii) During the three and six months ended June 30, 2023, as a result of the exit of the U.S. operations, the Company recognized an impairment charge of $205 related to the right-of-use lease assets associated with the Company’s former U.S. manufacturing facility in Los Angeles, California. The following tables present the Company's discontinued operations revenue by major product category: Three months ended June 30, 2023 2023 2022 Cannabis extracts $ 380 $ 1,459 Net revenue $ 380 $ 1,459 Six months ended June 30, 2023 2022 Cannabis extracts $ 1,029 $ 3,787 Net revenue $ 1,029 $ 3,787 The following table presents a reconciliation of assets and liabilities of the discontinued operations presented in the condensed consolidated balance sheets: As of June 30, 2023 As of December 31, 2022 Assets Current assets Cash and cash equivalents $ 1,918 $ 2,300 Accounts receivable, net 7 253 Other receivables — 775 Prepaids and other current assets 53 464 Inventory, net — 934 Current assets of discontinued operations 1,978 4,726 Non-current assets Property, plant and equipment, net — 254 Right-of-use assets — 430 Intangible assets, net — 1,594 Non-current assets of discontinued operations — 2,278 Liabilities Current liabilities Accounts payable 131 166 Accrued liabilities 621 807 Current portion of lease obligation 216 415 Current liabilities of discontinued operations $ 968 $ 1,388
Schedule of Plan Information and Restructuring-Related Costs	The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023 and 2022: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 102 $ 292 $ (328) $ 66 Total $ 102 $ 292 $ (328) $ 66 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,345 $ (1,279) $ 66 Total $ — $ 1,345 $ (1,279) $ 66 The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022: Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 1,152 $ 140 $ (470) $ 822 Other Restructuring Costs 144 838 (961) 21 Total $ 1,296 $ 978 $ (1,431) $ 843 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,590 $ (768) $ 822 Other Restructuring Costs — 1,419 (1,398) 21 Total $ — $ 3,009 $ (2,166) $ 843

Inventory, net (Tables)

Inventory, net (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, net	Inventory, net is comprised of the following items: As of June 30, 2023 As of December 31, 2022 Raw materials $ 7,419 $ 7,421 Work-in-progress 15,926 15,646 Finished goods 20,730 13,503 Supplies and consumables 1,115 989 Total $ 45,190 $ 37,559

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Associates and Joint Ventures	A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of June 30, 2023 As of December 31, 2022 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 17,646 $ 18,755 $ 17,646 $ 18,755 On June 30, 2023, the Company received a dividend of C$1,750 ($1,322) from Cronos GrowCo, which reduced the Company’s carrying amount in the investment. The following is a summary of the Company’s share of net gain (loss) from equity method investments: For the three months ended June 30, For the six months ended June 30, 2023 2022 2023 2022 Cronos GrowCo $ 270 $ 5,197 $ (226) $ 5,197 $ 270 $ 5,197 $ (226) $ 5,197
Summary of Gain on Revaluation of Other Investments	The following table summarizes the Company’s other investments activity: As of April 1, 2023 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 13,833 5,194 — (102) 18,925 $ 62,833 $ 5,194 $ — $ (102) $ 67,925 As of January 1, 2023 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2023 PharmaCann $ 49,000 $ — $ — $ — $ 49,000 Vitura 21,993 (2,729) — (339) 18,925 $ 70,993 $ (2,729) $ — $ (339) $ 67,925 As of April 1, 2022 Unrealized loss Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 99,154 $ — $ — $ — $ 99,154 Vitura 12,607 (2,200) — (892) 9,515 $ 111,761 $ (2,200) $ — $ (892) $ 108,669 As of January 1, 2022 Unrealized gain Impairment charges Foreign exchange effect As of June 30, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Vitura 8,000 1,996 — (481) 9,515 $ 118,392 $ 1,996 $ (11,238) $ (481) $ 108,669

Loans Receivable, net (Tables)

Loans Receivable, net (Tables)	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Schedule of Loans Receivable	Loans receivable, net consists of the following: As of June 30, 2023 As of December 31, 2022 GrowCo Credit Facility $ 5,035 $ 4,427 Add: Current portion of accrued interest — 4,463 Total current portion of loans receivable 5,035 8,890 GrowCo Credit Facility 55,757 56,898 Mucci Promissory Note 13,383 13,438 Cannasoul Collaboration Loan 1,736 1,837 Add: Long-term portion of accrued interest 204 172 Total long-term portion of loans receivable 71,080 72,345 Total loans receivable, net $ 76,115 $ 81,235
Schedule of Expected Credit Loss Allowances	Expected credit loss allowances on the Company’s long-term financial assets for the three and six months ended June 30, 2023 and 2022 were comprised of the following items: As of April 1, 2023 Increase (decrease) (i) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 11,719 $ (379) $ 239 $ 11,579 Mucci Promissory Note 91 (7) 2 86 Cannasoul Collaboration Loan 514 4 (15) 503 $ 12,324 $ (382) $ 226 $ 12,168 As of April 1, 2022 Increase (decrease) (i) Foreign exchange effect As of June 30, 2022 GrowCo Credit Facility $ 14,354 $ (660) $ (401) $ 13,293 Mucci Promissory Note 93 1 (3) 91 Cannasoul Collaboration Loan 409 4 (36) 377 $ 14,856 $ (655) $ (440) $ 13,761 As of January 1, 2023 Increase (decrease) (i) Foreign exchange effect As of June 30, 2023 GrowCo Credit Facility $ 12,455 $ (1,149) $ 273 $ 11,579 Mucci Promissory Note 89 (5) 2 86 Cannasoul Collaboration Loan 522 8 (27) 503 $ 13,066 $ (1,146) $ 248 $ 12,168 As of January 1, 2022 Increase (decrease) Foreign exchange effect As of June 30, 2022 GrowCo Credit Facility $ 14,089 $ (664) $ (132) $ 13,293 Mucci Promissory Note 90 2 (1) 91 Cannasoul Collaboration Loan 415 7 (45) 377 $ 14,594 $ (655) $ (178) $ 13,761 (i) During the three and six months ended June 30, 2023, $382 and $1,146, respectively, were recorded as decreases to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of principal and interest payments made by Cronos GrowCo reducing our expected credit losses on loans receivable. During both the three and six months ended June 30, 2022, $655 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net loss and comprehensive income (loss) as a result of adjustments to our expected credit losses.

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Reconciliation of Derivative Liabilities Activity	Reconciliation of the Company’s derivative liabilities activity are as follows: As of April 1, 2023 Revaluation (gain) loss Foreign exchange effect As of June 30, 2023 Pre-emptive Rights $ 79 $ (43) $ 1 $ 37 Top-up Rights 1 — (1) — $ 80 $ (43) $ — $ 37 As of April 1, 2022 Revaluation gain Foreign exchange effect As of June 30, 2022 Altria Warrant $ 3,845 $ (3,245) $ (109) $ 491 Pre-emptive Rights 67 (49) (2) 16 Top-up Rights 187 (116) (4) 67 $ 4,099 $ (3,410) $ (115) $ 574 As of January 1, 2023 Revaluation (gain) loss Foreign exchange effect As of June 30, 2023 Pre-emptive Rights $ — $ 36 1 $ 37 Top-up Rights 15 (14) (1) — $ 15 $ 22 $ — $ 37 As of January 1, 2022 Revaluation gain Foreign exchange effect As of June 30, 2022 Altria Warrant $ 13,720 $ (13,256) $ 27 $ 491 Pre-emptive Rights 180 (164) — 16 Top-up Rights 475 (409) 1 67 $ 14,375 $ (13,829) $ 28 $ 574
Schedule of Fair Values of Derivative Liabilities	The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of June 30, 2023 Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $2.61 $2.61 Subscription price (per share in C$) $16.25 $16.25 Weighted-average risk-free interest rate (i) 4.72% 4.86% Weighted-average expected life (in years) (ii) 1.50 1.10 Expected annualized volatility (iii) 59% 59% Expected dividend yield —% —% As of December 31, 2022 Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $3.44 $3.44 Subscription price (per share in C$) $16.25 $16.25 Weighted-average risk-free interest rate (i) 4.14% 4.28% Weighted-average expected life (in years) (ii) 0.25 0.59 Expected annualized volatility (iii) 73% 73% Expected dividend yield —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2023 and December 31, 2022, the risk-free interest rate uses a range of approximately 4.46% to 4.89% and 3.81% to 4.37%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2023 and December 31, 2022, the expected life uses a range of approximately 1.00 years to 2.25 years and 0.25 years to 2.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Plan Information and Restructuring-Related Costs	The following tables summarize the Company’s discontinued operations restructuring activity for the three and six months ended June 30, 2023 and 2022: Accrual as of April 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of January 1, 2023 Expenses Payments/Write-offs Accrual as of June 30, 2023 Employee Termination Benefits $ — $ 442 $ (223) $ 219 Other Restructuring Costs — 92 — 92 Total $ — $ 534 $ (223) $ 311 Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 102 $ 292 $ (328) $ 66 Total $ 102 $ 292 $ (328) $ 66 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,345 $ (1,279) $ 66 Total $ — $ 1,345 $ (1,279) $ 66 The following table summarizes the Company’s restructuring activity for the three and six months ended June 30, 2022: Accrual as of April 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ 1,152 $ 140 $ (470) $ 822 Other Restructuring Costs 144 838 (961) 21 Total $ 1,296 $ 978 $ (1,431) $ 843 Accrual as of January 1, 2022 Expenses Payments/Write-offs Accrual as of June 30, 2022 Employee Termination Benefits $ — $ 1,590 $ (768) $ 822 Other Restructuring Costs — 1,419 (1,398) 21 Total $ — $ 3,009 $ (2,166) $ 843

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table summarizes the total share-based compensation expense associated with the Company’s stock options, RSUs and liability-classified awards for the three and six months ended June 30, 2023 and 2022: Three months ended June 30, For the six months ended June 30, 2023 2022 2023 2022 Stock options $ 372 $ 1,141 $ 1,106 $ 2,870 RSUs 1,959 1,442 3,760 3,329 Total share-based compensation $ 2,331 $ 2,583 $ 4,866 $ 6,199
Summary of the Changes in Options and Options Outstanding	The following is a summary of the changes in stock options for the six months ended June 30, 2023 and 2022: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2023 $ 10.57 5,350,600 0.73 Issuance of options 2.96 188,317 Cancellation, forfeiture and expiry of options 7.75 (3,435,716) Balance as of June 30, 2023 $ 14.50 2,103,201 2.34 Exercisable as of June 30, 2023 $ 18.72 1,426,612 1.00 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.11 (1,481,004) Cancellation, forfeiture and expiry of options 13.56 (89,251) Balance as of June 30, 2022 $ 8.61 7,369,075 1.53 Exercisable as of June 30, 2022 $ 8.28 4,686,991 1.04 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of June 30, 2023 As of December 31, 2022 2020 Omnibus Plan 702,264 2,788,947 2018 Stock Option Plan 1,400,937 1,422,069 2015 Stock Option Plan — 1,139,584 Total stock options outstanding 2,103,201 5,350,600
Summary of Fair Value of Options Issued	The fair value of the options issued during the period was determined using the Black-Scholes option pricing model, using the following inputs: 2023 Share price at grant date (per share) $2.96 Exercise price (per option) $2.96 Risk-free interest rate 3.22% Expected life of options (in years) 7 Expected annualized volatility 72.68% Expected dividend yield — Weighted average Black-Scholes value at grant date (per option) $2.07 Forfeiture rate —
Summary of Changes in RSUs	The following is a summary of the changes in RSUs for the six months ended June 30, 2023 and 2022: Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2023 $ 4.63 5,725,470 Granted (i) 2.66 2,819,174 Vested and issued 5.04 (735,523) Cancellation and forfeitures 3.93 (254,382) Balance as of June 30, 2023 $ 3.87 7,554,739 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 4.32 4,513,992 Vested and issued 8.58 (722,721) Cancellation and forfeitures 8.32 (101,561) Balance as of June 30, 2022 $ 4.84 4,915,580 (i) RSUs granted in the period vest annually in equal installments over a three-year period from either the grant date or after a three
Summary of Changes in DSUs and Warrants	The following is a summary of the changes in DSUs for the six months ended June 30, 2023 and 2022: Financial liability Number of DSUs Balance as of January 1, 2023 $ 674 265,732 Gain on revaluation (150) — Balance as of June 30, 2023 $ 524 265,732 Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (161) — Balance as of June 30, 2022 $ 247 104,442

Loss per Share (Tables)

Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Basic and diluted loss per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Basic and diluted loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (5,526) $ (17,410) $ (23,473) $ (45,760) Weighted-average number of common shares outstanding for computation for basic and diluted loss per share (i) 380,961,682 376,031,860 380,792,802 375,530,077 Basic loss from continuing operations per share $ (0.01) $ (0.05) $ (0.06) $ (0.12) Diluted loss per share from continuing operations $ (0.01) $ (0.05) $ (0.06) $ (0.12) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (2,834) $ (2,811) $ (4,056) $ (7,099) Weighted-average number of common shares outstanding for computation for basic and diluted loss per share (i) 380,961,682 376,031,860 380,792,802 375,530,077 Basic loss from discontinued operations per share $ (0.01) $ 0.00 $ (0.01) $ (0.02) Diluted loss from discontinued operations per share $ (0.01) $ 0.00 $ (0.01) $ (0.02) (i) In computing diluted loss per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Risks and Uncertainties [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2023 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 409,428 $ — $ — $ 409,428 Short-term investments 431,510 — — 431,510 Other investments (i) 18,925 — — 18,925 Derivative liabilities — — 37 37 December 31, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 764,644 $ — $ — $ 764,644 Short-term investments 113,077 — — 113,077 Other investments (i) 21,993 — — 21,993 Derivative liabilities — — 15 15 (i) As of June 30, 2023 and December 31, 2022, the Company’s influence on Vitura is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 4 “Investments” for additional information.
Schedule of Fair Value of Assets Measured on Nonrecurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: As of June 30, 2023 Level 1 Level 2 Level 3 Total Other investments (i) — — 49,000 49,000 As of December 31, 2022 Level 1 Level 2 Level 3 Total Other investments (i) — — 49,000 49,000 (i) On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. On February 28, 2022, PharmaCann closed its previously announced transaction with LivWell Holdings Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (“the LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully diluted basis decreased to approximately 6.4%. As of both June 30, 2023 and December 31, 2022, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.3%. See Note 4 “ Investments .”

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Cronos GrowCo - purchases $ 6,549 $ 5,597 $ 14,015 $ 8,815

Background, Basis of Presenta_4

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($) segment	Mar. 31, 2023 segment	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Concentration Risk [Line Items]
Number of reportable segments | segment	1	2
Number of operating segments | segment	1
Maximum exposure to credit risk				$ 943,884		$ 987,836
Current expected credit loss allowance on accounts receivable	$ 69			69		$ 219
Net revenue, before excise taxes	25,798		$ 27,095	$ 52,352	$ 54,173
Three Major Customers
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 16,839
Accounts Receivable | Two Customers | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage				41%
Accounts Receivable | Three Customers | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage						55%
Revenue Benchmark | Three Major Customers | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	67%		59%	67%	56%
Net revenue, before excise taxes			$ 12,767	$ 34,732	$ 24,690

Background, Basis of Presenta_5

Background, Basis of Presentation, and Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Net revenue	$ 19,021	$ 21,602	$ 38,516	$ 44,307
Canada
Segment Reporting Information [Line Items]
Net revenue	13,595	14,389	28,029	27,965
Israel
Segment Reporting Information [Line Items]
Net revenue	5,426	7,213	10,487	16,342
Cannabis flower
Segment Reporting Information [Line Items]
Net revenue	14,014	15,739	27,142	34,364
Cannabis extracts
Segment Reporting Information [Line Items]
Net revenue	4,926	5,582	11,227	9,570
Other
Segment Reporting Information [Line Items]
Net revenue	$ 81	$ 281	$ 147	$ 373

Discontinued Operations - Major

Discontinued Operations - Major Components Comprising Loss from Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses
Net loss from discontinued operations	$ (2,834)	$ (2,811)	$ (4,056)	$ (7,099)
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	380	1,459	1,029	3,787
Cost of sales	848	1,661	2,044	3,773
Inventory write-down	839	0	839	0
Gross profit	(1,307)	(202)	(1,854)	14
Operating expenses
Sales and marketing	387	1,397	518	3,399
Research and development	18	108	20	226
General and administrative	213	719	736	1,956
Restructuring costs	534	292	534	1,345
Share-based compensation	5	33	21	103
Depreciation and amortization	5	13	13	38
Impairment loss on long-lived assets	205	0	205	0
Total operating expenses	1,367	2,562	2,047	7,067
Interest income	3	0	8	1
Other, net	(163)	(47)	(163)	(47)
Total other loss	(160)	(47)	(155)	(46)
Loss before income taxes	(2,834)	(2,811)	(4,056)	(7,099)
Income tax expense (benefit)	0	0	0	0
Net loss from discontinued operations	(2,834)	$ (2,811)	(4,056)	$ (7,099)
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment | Facility in Los Angeles, California
Operating expenses
Impairment loss on long-lived assets	$ 205		$ 205

Discontinued Operations - Reven

Discontinued Operations - Revenue by Major Product Category (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 380	$ 1,459	$ 1,029	$ 3,787
Cannabis extracts
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 380	$ 1,459	$ 1,029	$ 3,787

Discontinued Operations - Restr

Discontinued Operations - Restructuring Activity (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	$ 0	$ 102	$ 0	$ 0
Expenses	534	292	534	1,345
Payments/Write-offs	(223)	(328)	(223)	(1,279)
Accrual, Ending Balance	311	66	311	66
Employee termination benefits
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	0	102	0	0
Expenses	442	292	442	1,345
Payments/Write-offs	(223)	(328)	(223)	(1,279)
Accrual, Ending Balance	219	$ 66	219	$ 66
Other restructuring costs
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	0		0
Expenses	92		92
Payments/Write-offs	0		0
Accrual, Ending Balance	$ 92		$ 92

Discontinued Operations - Recon

Discontinued Operations - Reconciliation of Assets and Liabilities of Discontinued Operations (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 1,918	$ 2,300
Accounts receivable, net	7	253
Other receivables	0	775
Prepaids and other current assets	53	464
Inventory, net	0	934
Current assets of discontinued operations	1,978	4,726
Non-current assets
Property, plant and equipment, net	0	254
Right-of-use assets	0	430
Intangible assets, net	0	1,594
Non-current assets of discontinued operations	0	2,278
Current liabilities
Accounts payable	131	166
Accrued liabilities	621	807
Current portion of lease obligation	216	415
Current liabilities of discontinued operations	$ 968	$ 1,388

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 1,298	$ 2,218
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of property, plant and equipment	$ 67	$ 133

Inventory, net (Details)

Inventory, net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 7,419	$ 7,421
Work-in-progress	15,926	15,646
Finished goods	20,730	13,503
Supplies and consumables	1,115	989
Inventory, net	$ 45,190	$ 37,559

Investments - Schedule of Inves

Investments - Schedule of Investments in Associates and Joint Ventures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Equity method investments, net	$ 17,646		$ 17,646		$ 18,755
Share of loss from equity method investments	$ 270	$ 5,197	$ (226)	$ 5,197
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50%		50%
Equity method investments, net	$ 17,646		$ 17,646		$ 18,755
Share of loss from equity method investments	$ 270	$ 5,197	$ (226)	$ 5,197

Investments - Narrative (Detail

Investments - Narrative (Details) $ in Thousands, $ in Thousands				3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 14, 2021 USD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2022	Feb. 28, 2022
Variable Interest Entity [Line Items]
Dividends received from equity method investment						$ 1,299	$ 0
Purchase of other investments			$ 110,392					$ 110,392
Impairment loss on other investments				$ 0	$ 0	0	11,238
PharmaCann
Variable Interest Entity [Line Items]
Impairment loss on other investments				$ 0	$ 0	$ 0	$ 11,238
Cronos GrowCo
Variable Interest Entity [Line Items]
Dividends received from equity method investment	$ 1,322	$ 1,750
PharmaCann
Variable Interest Entity [Line Items]
Ownership interest	6.30%	6.30%		6.30%		6.30%		10.50%	6.30%	6.40%
Vitura
Variable Interest Entity [Line Items]
Ownership interest	10%	10%		10%		10%
PharmaCann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares			473,787					473,787

Investments - Revaluation of Ot

Investments - Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Other Investments [Roll Forward]
Other investments, beginning balance	$ 62,833	$ 111,761	$ 70,993	$ 118,392
Unrealized gain (loss)	5,194	(2,200)	(2,729)	1,996
Impairment charges	0	0	0	(11,238)
Foreign exchange effect	(102)	(892)	(339)	(481)
Other investments, ending balance	67,925	108,669	67,925	108,669
PharmaCann
Other Investments [Roll Forward]
Other investments, beginning balance	49,000	99,154	49,000	110,392
Unrealized gain (loss)	0	0	0	0
Impairment charges	0	0	0	(11,238)
Foreign exchange effect	0	0	0	0
Other investments, ending balance	49,000	99,154	49,000	99,154
Vitura
Other Investments [Roll Forward]
Other investments, beginning balance	13,833	12,607	21,993	8,000
Unrealized gain (loss)	5,194	(2,200)	(2,729)	1,996
Impairment charges	0	0	0	0
Foreign exchange effect	(102)	(892)	(339)	(481)
Other investments, ending balance	$ 18,925	$ 9,515	$ 18,925	$ 9,515

Loans Receivable, net - Schedul

Loans Receivable, net - Schedule of Loan Receivable (Details) ₪ in Thousands, $ in Thousands			6 Months Ended			12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2023 ILS (₪)	Dec. 31, 2022 ILS (₪)	Sep. 30, 2022	Aug. 31, 2021 CAD ($)	Aug. 23, 2019 CAD ($)	Jun. 28, 2019 USD ($)	Jun. 28, 2019 CAD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable	$ 5,035		$ 5,035			$ 8,890
Total long-term portion of loans receivable	71,080		71,080			72,345
Total loans receivable, net	76,115		76,115			81,235
Proceeds from repayment on loan receivables			11,388		$ 1,573
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Current portion of accrued interest	0		0			4,463
Add: Long-term portion of accrued interest	204		204			172
Loans Receivable | GrowCo Credit Facility
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	5,035		5,035			4,427
Long term portion of loans receivable, before accrued interest	$ 55,757		55,757			56,898
Face amount												$ 105,000,000	$ 100,000,000
Draw downs			78,538	$ 104,000,000		76,730	$ 104,000,000
Quarterly payment								$ 1,000,000
Proceeds from repayment on loan receivables			6,167	8,167,000
Proceeds from interest on loan receivables			$ 12,450	$ 16,486,000
Loans Receivable | GrowCo Credit Facility | Canadian Prime Rate
Accounts, Notes, Loans and Financing Receivable [Line Items]
Basis spread on interest rate	1.25%		1.25%					1.25%	1.25%
Loans Receivable | Mucci Promissory Note
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	$ 13,383		$ 13,383			13,438
Face amount														$ 12,347	$ 16,350,000
Proceeds from repayment on loan receivables	1,322	$ 1,750,000
Proceeds from interest on loan receivables	897	1,187,000
Proceeds from repayment on loan outstanding principal	425	$ 563,000
Stated interest rate														3.95%	3.95%
Loans Receivable | Mucci Promissory Note | Canadian Prime Rate
Accounts, Notes, Loans and Financing Receivable [Line Items]
Basis spread on interest rate											1.25%
Loans Receivable | Cannasoul Collaboration Loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	1,736		1,736			1,837
Loans Receivable | Cannasoul Collaboration Loan | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Cannasoul | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received	$ 2,239		$ 2,239			$ 2,359			₪ 8,297	₪ 8,297

Loans Receivable, net - Sched_2

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 12,324	$ 14,856	$ 13,066	$ 14,594
Increase (decrease)	(382)	(655)	(1,146)	(655)
Foreign exchange effect	226	(440)	248	(178)
Ending balance	12,168	13,761	12,168	13,761
GrowCo Credit Facility | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	11,719	14,354	12,455	14,089
Increase (decrease)	(379)	(660)	(1,149)	(664)
Foreign exchange effect	239	(401)	273	(132)
Ending balance	11,579	13,293	11,579	13,293
Mucci Promissory Note | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	91	93	89	90
Increase (decrease)	(7)	1	(5)	2
Foreign exchange effect	2	(3)	2	(1)
Ending balance	86	91	86	91
Cannasoul Collaboration Loan | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	514	409	522	415
Increase (decrease)	4	4	8	7
Foreign exchange effect	(15)	(36)	(27)	(45)
Ending balance	$ 503	$ 377	$ 503	$ 377

Derivative Liabilities - Narrat

Derivative Liabilities - Narrative (Details) - $ / shares	Mar. 08, 2019	Jun. 30, 2023
Altria Group, Inc. | Cronos Group, Inc.
Derivative [Line Items]
Balance held (in shares)		156,573,537
Ownership interest		41%
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share)	$ 16.25
Exercise rights, minimum ownership percentage	20%
Top-up Rights
Derivative [Line Items]
Exercise price (in dollars per share)	$ 16.25
Exercise rights, minimum ownership percentage	20%
Exercise price, volume-weighted average price, measurement period	10 days
Exercise price, volume-weighted average price, measurement period, days preceding exercise	10 days

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Derivative Instruments [Roll Forward]
Beginning balance	$ 80	$ 4,099	$ 15	$ 14,375
Revaluation (gain) loss	(43)	(3,410)	22	(13,829)
Foreign exchange effect	0	(115)	0	28
Ending balance	37	574	37	574
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance		3,845		13,720
Revaluation (gain) loss		(3,245)		(13,256)
Foreign exchange effect		(109)		27
Ending balance		491		491
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	79	67	0	180
Revaluation (gain) loss	(43)	(49)	36	(164)
Foreign exchange effect	1	(2)	1	0
Ending balance	37	16	37	16
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	1	187	15	475
Revaluation (gain) loss	0	(116)	(14)	(409)
Foreign exchange effect	(1)	(4)	(1)	1
Ending balance	$ 0	$ 67	$ 0	$ 67

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2023 $ / shares	Dec. 31, 2022 $ / shares
Pre-emptive Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.61	3.44
Pre-emptive Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.59	0.73
Pre-emptive Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0472	0.0414
Pre-emptive Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 6 months	3 months
Top-up Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.61	3.44
Top-up Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.59	0.73
Top-up Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0486	0.0428
Top-up Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 1 month 6 days	7 months 2 days
Pre-emptive Rights and Top-up Rights | Minimum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0446	0.0381
Pre-emptive Rights and Top-up Rights | Minimum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year	3 months
Pre-emptive Rights and Top-up Rights | Maximum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0489	0.0437
Pre-emptive Rights and Top-up Rights | Maximum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	2 years 3 months	2 years 9 months

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 0	$ 978	$ 0	$ 3,009
Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 978		$ 3,009

Restructuring - Restructuring A

Restructuring - Restructuring Activity (Details) - Realignment - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	$ 1,296	$ 0
Expenses	978	3,009
Payments/Write-offs	(1,431)	(2,166)
Accrual, Ending Balance	843	843
Employee termination benefits
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	1,152	0
Expenses	140	1,590
Payments/Write-offs	(470)	(768)
Accrual, Ending Balance	822	822
Other restructuring costs
Restructuring Reserve [Roll Forward]
Accrual, Beginning Balance	144	0
Expenses	838	1,419
Payments/Write-offs	(961)	(1,398)
Accrual, Ending Balance	$ 21	$ 21

Share-based Compensation - Summ

Share-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 2,331	$ 2,583	$ 4,866	$ 6,199
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	372	1,141	1,106	2,870
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 1,959	$ 1,442	$ 3,760	$ 3,329

Share-based Compensation - Stoc

Share-based Compensation - Stock Options Narrative (Details) - Stock options	6 Months Ended
	Jun. 30, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in dollars per share)	$ 2.96
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in dollars per share)	$ 2.07

Share-based Compensation - Su_2

Share-based Compensation - Summary of the Changes in Options (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 10.57	$ 7.75	$ 7.75
Issuance of options (in dollars per share)	2.96
Exercise of options (in dollars per share)		3.11
Cancellation, forfeiture and expiry of options (in dollars per share)	7.75	13.56
Balance at end of period (in dollars per share)	14.50	8.61	$ 10.57	$ 7.75
Weighted average exercise price of options exercisable (in dollars per share)	$ 18.72	$ 8.28
Number of options
Balance at beginning of period (in shares)	5,350,600	8,939,330	8,939,330
Issuance of options (in shares)	188,317
Exercise of options (in shares)		(1,481,004)
Cancellation, forfeiture and expiry of options (in shares)	(3,435,716)	(89,251)
Balance at end of period (in shares)	2,103,201	7,369,075	5,350,600	8,939,330
Exercisable (in shares)	1,426,612	4,686,991
Weighted-average remaining contractual term (years)
Outstanding	2 years 4 months 2 days	1 year 6 months 10 days	8 months 23 days	2 years 8 months 12 days
Exercisable	1 year	1 year 14 days

Share-based Compensation - Su_3

Share-based Compensation - Summary of Fair Value of Options Issued (Details) - Stock options	6 Months Ended
	Jun. 30, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price at grant date (in dollars per share)	$ 2.96
Exercise price (per option) (in dollars per share)	$ 2.96
Risk-free interest rate	3.22%
Expected life of options (in years)	7 years
Expected annualized volatility	72.68%
Expected dividend yield	0%
Black-Scholes value at grant date (per option) (in dollars per share)	$ 2.07
Forfeiture rate	0%

Share-based Compensation - Sche

Share-based Compensation - Schedule of Stock Options Outstanding (Details) - shares	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,103,201	5,350,600	7,369,075	8,939,330
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	702,264	2,788,947
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	1,400,937	1,422,069
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	0	1,139,584

Share-based Compensation - Su_4

Share-based Compensation - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Weighted-average grant date fair value
Balance at beginning of period (in dollars per share)	$ 4.63	$ 9.22
Granted (in dollars per share)	2.66	4.32
Vested and issued (in dollars per share)	5.04	8.58
Cancellation and forfeitures (in dollars per share)	3.93	8.32
Balance at end of period (in dollars per share)	$ 3.87	$ 4.84
Number of awards
Balance at beginning of period (in shares)	5,725,470	1,225,870
Granted (in shares)	2,819,174	4,513,992
Vested and issued (in shares)	(735,523)	(722,721)
Cancellation and forfeitures (in shares)	(254,382)	(101,561)
Balance at end of period (in shares)	7,554,739	4,915,580
Vesting period	3 years
Minimum
Number of awards
Cliff period	3 years
Maximum
Number of awards
Cliff period	5 years

Share-based Compensation - Su_5

Share-based Compensation - Summary of DSU Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Financial liability
Balance at beginning of period	$ 674	$ 408
Gain on revaluation	(150)	(161)
Balance at end of period	$ 524	$ 247
Number of awards
Balance at beginning of period (in shares)	265,732	104,442
Balance at end of period (in shares)	265,732	104,442

Loss per Share - Schedule of Ea

Loss per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Basic and diluted loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$ (5,526)	$ (17,410)	$ (23,473)	$ (45,760)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ (2,834)	$ (2,811)	$ (4,056)	$ (7,099)
Weighted-average number of common shares outstanding for computation for basic loss per share (in shares)	380,961,682	376,031,860	380,792,802	375,530,077
Weighted-average number of common shares outstanding for computation for diluted loss per share (in shares)	380,961,682	376,031,860	380,792,802	375,530,077
Basic earnings (loss) from continuing operations per share (in dollars per share)	$ (0.01)	$ (0.05)	$ (0.06)	$ (0.12)
Diluted earnings (loss) from continuing operations per share (in dollars per share)	(0.01)	(0.05)	(0.06)	(0.12)
Basic loss from discontinued operations per share (in dollars per share)	(0.01)	0	(0.01)	(0.02)
Diluted earnings (loss) from discontinued operations per share (in dollars per share)	$ (0.01)	$ 0	$ (0.01)	$ (0.02)
Total anti-dilutive securities (in shares)	28,769,758	119,589,123	29,428,093	118,906,603

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands, ₪ in Millions	Apr. 17, 2023 ILS (₪) defendant	Oct. 24, 2022 CAD ($)	Mar. 12, 2020 complaint shareholder
U.S. District Court of Eastern District of New York Vs. Cronos | Pending Litigation
Loss Contingencies [Line Items]
Number of alleged shareholders | shareholder			2
Number of putative class action complaints | complaint			2
OSC Settlement | Settled Litigation
Loss Contingencies [Line Items]
Payments for legal settlements | $		$ 1,340
Green Leaf Vs. Cronos
Loss Contingencies [Line Items]
Number of defendants	26
Damages sought | ₪	₪ 420
Green Leaf Vs. Cronos | Cronos Group, Inc.
Loss Contingencies [Line Items]
Number of defendants	3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 409,428	$ 764,644
Short-term investments	431,510	113,077
Other investments	18,925	21,993
Derivative liabilities	37	15
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	409,428	764,644
Short-term investments	431,510	113,077
Other investments	18,925	21,993
Derivative liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	$ 37	$ 15

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Assets Measured on Nonrecurring Basis (Details) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 14, 2021	Dec. 31, 2021	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Feb. 28, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments		$ 118,392	$ 67,925	$ 62,833	$ 70,993	$ 108,669	$ 111,761
Sale of stock, price per share (in dollars per share)	$ 0.0001
Sale of stock, percentage of ownership after transaction	10.50%
Purchase of other investments	$ 110,392	$ 110,392
PharmaCann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ownership interest		10.50%	6.30%		6.30%			6.40%
PharmaCann
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	473,787	473,787
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments			$ 49,000		$ 49,000
Fair Value, Nonrecurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments			0		0
Fair Value, Nonrecurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments			0		0
Fair Value, Nonrecurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments			$ 49,000		$ 49,000

Impairment Loss on Long-lived_2

Impairment Loss on Long-lived Assets (Details) ft² in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) ft²
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment charge related to right-of-use lease asset				$ 1,986
Lease impairment, area of land (in sq ft) | ft²				29
Impairment loss on long-lived assets	$ 0	$ 0	$ 0	$ 3,493
Leasehold Improvements
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets				$ 1,507

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Accounts payable	$ 9,340,000		$ 9,340,000		$ 11,163,000
Cannabis Purchases | Related Party
Related Party Transaction [Line Items]
Purchases	6,549,000	$ 5,597,000	14,015,000	$ 8,815,000
Accounts payable	2,682,000		2,682,000		2,519,000
Manufacturing Services | Immediate Family Member of Management or Principal Owner
Related Party Transaction [Line Items]
Purchases	603,000		1,436,000
Accounts payable	$ 45,000		$ 45,000		$ 0
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest	50%		50%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Thousands	Aug. 04, 2023 USD ($)
Cost Reductions
Subsequent Event [Line Items]
Expected restructuring charges	$ 2,000
Discontinued Operations, Held-for-sale | Facility Closing
Subsequent Event [Line Items]
Expected restructuring charges	$ 1,200